Schymura et al. BMC Cancer 2010, 10:152 http://www.biomedcentral.com/1471-2407/10/152 Page 14 of 15 Table 6: Five-year survival and crude and adjusted hazard ratios by sociodemograhic and clinical factors (n = 3,297). ≤1 year post diagnosis 0 1 2+ 0 1 2+ 0 1 2+ >1 to 3 years post diagnosis >3 years post diagnosis 86.69# 79.68# 62.62# 1.00 2.84 9.90 1.00 1.56 3.99 1.00 1.48 2.16 (referent) (1.39 - 5.81) (4.78 - 20.88) (referent) (1.08 - 2.26) (2.52 - 6.31) (referent) (1.09 - 2.00) (1.30 - 3.58) 1.00 2.16 6.39 1.00 1.20 2.67 1.00 1.22 1.47 (referent) (1.05 - 4.41) (3.04 - 13.42) (referent) (0.83 - 1.74) (1.68 - 4.25) (referent) (0.90 - 1.66) (0.88 - 2.45) 1: 5-year survival following diagnosis conditional on having survived the first six months following diagnosis. 2: OR = odds ratio; CI = confidence interval. 3: Adjusted for factors shown in the table. 4: Hazard associated with comorbidity is time dependent. #: 5 year survival percent (not stratified by time since diagnosis) Acknowledgements The authors gratefully acknowledge all the staff in the participating registries and in the CDC Division of Cancer Prevention and Control who contributed to the development and conduct of this study. The authors would also like to acknowledge Jen Wike for her logistic support, Lisa Richardson for her clinical expertise, and Trevor Thompson and Susan Sabatino for their assistance with the survival analysis. Author Details 1New York State Cancer Registry, New York State Department of Health, 150 Broadway, Suite 361, Menands, NY 12204-2719, USA, 2Division of Cancer Prevention and Control, Centers for Disease Control and Prevention, Atlanta, GA, USA, 3Louisiana Tumor Registry, Louisiana State University Health Sciences Center, New Orleans, LA, USA, 4California Cancer Registry, Public Health Institute, Sacramento, CA, USA, 5Colorado Central Cancer Registry, Colorado Department of Public Health and Environment, Denver, CO, USA, 6Rhode Island Cancer Registry, Rhode Island Department of Health, Providence, RI, USA , 7Division of Epidemiologic Studies, Illinois Department of Public Health, Springfield, IL, USA and 8South Carolina Central Cancer Registry, South Carolina Department of Health and Environmental Control, Columbia, SC, USA Received: 19 November 2009 Accepted: 19 April 2010 Published: 19 April 2010 TB©hM2isC0ia1Csr0taiSncleOhriyps2mea0nuv1Aar0ic,lae1bt0sla:e1l;5farl2ioctmiecnl:eshedteispBt:ri/obwMuwetdwC.bueiondmtraerldtLhctedn.etraml.csomft/h1e47C1re-2a4ti0v7e/C10o/m15m2onsAt ributionLicense(ht p:/ creativecommons.org/licenses/by/2.0),whichpermitsunrestricteduse,distribution,andreproductioninanymedium,providedtheoriginalworkisproperlycited. References 1. Institute of Medicine: Ensuring Quality Cancer Care Washington, DC: National Academy Press; 1999. 2. Institute of Medicine: Enhancing Data Systems to Improve the Quality of Cancer Care Washington, DC: National Academy Press; 2000. 3. National Cancer Institute Physician Data Query (PDQ): Prostate Cancer Treatment (PDQ) Health Professional Version (updated 12/1996) 1996 [http:// www.cancer.gov]. 4. National Cancer Institute Physician Data Query (PDQ): Prostate Cancer Treatment (PDQ) Health Professional Version (last modified 7/2/2008) 2009 [http://www.cancer.gov]. 5. NCCN Clinical Practice Guidelines in Oncology: Prostate Cancer (Version 2.2009) 2009 [http://www.NCCN.org]. 6. McDavid K, Schymura MJ, Armstrong L, Santilli L, Schmidt B, Byers T, et al.: Rationale and design of the National Program of Cancer Registries' Breast, Colon, and Prostate Cancer Patterns of Care Study. Cancer Causes Control 2004, 15:1057-1066. 7. Alley LG, Chen VW, Wike JM, Schymura MJ, Rycroft RK, Shen T, et al.: CDC- NPCR's Breast, Colon, and Prostate Cancer Data Quality and Patterns of Care Study: Overview and Methodology. J Registry Mgmt 2007, 34:148-157. 8. American Joint Committee on Cancer: Manual for Staging of Cancer 4th edition. Philadelphia: J. B. Lippincott Company; 1992. 9. Deyo RA, Cherkin DC, Ciol MA: Adapting a clinical comorbidity index for use with ICD-9-CM administrative databases. J Clin Epidemiol 1992, 45:613-619. 10. Krieger N: Overcoming the absence of socioeconomic data in medical records: validation and application of a census-based methodology. Am J Public Health 1992, 82:703-710. 11. Harlan LC, Potosky A, Gilliland FD, Hoffman R, Albertsen PC, Hamilton AS, et al.: Factors associated with initial therapy for clinically localized prostate cancer: prostate cancer outcomes study. J Natl Cancer Inst 2001, 93:1864-1871. 12. National Cancer Institute, DCCPS, Surveillance Research Program, Cancer Statistics Branch: Surveillance, Epidemiology, and End Results (SEER) Program Limited-Use Data (1973-2002). 2005. 13. National Cancer Database, Commission on Cancer, American College of Surgeons: Stage/Treatment/Surgery of Prostate Cancer Diagnosed in 1998, Benchmark Reports, V9.0. 2008. 14. Byers T, Bott R, Palmer L, Finch J, Prindiville S, Berg J, et al.: Monitoring the quality of cancer care in Colorado: Special project Englewood, CO: Colorado Foundation for Medical Care; 1998. 15. Harlan L, Brawley O, Pommerenke F, Wali P, Kramer B: Geographic, age, and racial variation in the treatment of local/regional carcinoma of the prostate. J Clin Oncol 1995, 13:93-100. 16. Klabunde CN, Potosky AL, Harlan LC, Kramer BS: Trends and black/white differences in treatment for nonmetastatic prostate cancer. Medical Care 1998, 36:1337-48. 17. Mettlin CJ, Murphy GP, Cunningham MP, Menck HR: The National Cancer Data Base report on race, age, and region variations in prostate cancer treatment. Cancer 1997, 80:1261-1266. 18. Spencer BA, Fung CH, Wang M, Rubenstein LV, Litwin MS: Geographic Variation across Veterans Affairs Medical Centers in the Treatment of Early Stage Prostate Cancer. J Urology 2004, 172:2362-2365.